Q3 2023 · 13F-HR
5AM Venture Management, LLCholdings as filed
Filed 2023-11-14 · accession 0001104659-23-118105
$347.5M
Reported value
26
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $70.5M | 20.3% | 5,160,975 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $69.7M | 20.0% | 4,408,379 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $20.6M | 5.93% | 438,442 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $20.1M | 5.79% | 1,472,264 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $17.9M | 5.14% | 313,210 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $13.7M | 3.96% | 462,286 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $13.5M | 3.88% | 6,361,723 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $12.3M | 3.53% | 587,600 | Common | SOLE |
| 75120L100 | — | RALLYBIO CORP | $12.2M | 3.52% | 3,630,724 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $9.8M | 2.83% | 490,000 | Common | SOLE |
| 810648105 | SCPH | SCPHARMACEUTICALS INC | $8.5M | 2.46% | 1,200,647 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $8.5M | 2.46% | 310,270 | Common | SOLE |
| 60468T105 | MRTXEUR | MIRATI THERAPEUTICS INC | $8.4M | 2.41% | 192,500 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $7.7M | 2.22% | 790,440 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $6.5M | 1.86% | 585,000 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $6.4M | 1.85% | 357,733 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $6.3M | 1.81% | 410,000 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $6.3M | 1.81% | 320,000 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $5.7M | 1.63% | 411,450 | Common | SOLE |
| 85209E109 | — | SPRUCE BIOSCIENCES INC | $5.3M | 1.54% | 2,364,000 | Common | SOLE |
| 438083107 | FIXXEUR | HOMOLOGY MEDICINES INC | $5.3M | 1.53% | 4,535,919 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $4.2M | 1.22% | 665,555 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $4.1M | 1.17% | 404,404 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $1.7M | 0.48% | 1,305,000 | Common | SOLE |
| 45258K109 | — | IMPEL PHARMACEUTICALS INC | $1.2M | 0.36% | 2,884,791 | Common | SOLE |
| 171757107 | — | CIDARA THERAPEUTICS INC | $1.1M | 0.31% | 1,134,511 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.